Medifast Inc(MED) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.33 | Insider Own | 6.23% | Shs Outstand | 11.2M | Perf Week | -4.89% |
| Market Cap | 0.13B | Forward P/E | - | EPS next Y | 75.65% | Insider Trans | 25.75% | Shs Float | 10.5M | Perf Month | 3.43% |
| Enterprise Value | -0.01B | PEG | - | EPS next Q | -0.35 | Inst Own | 74.23% | Short Float | 17.41% | Perf Quarter | -0.74% |
| Income | -0.03B | P/S | 0.43 | EPS this Y | -91.67% | Inst Trans | -9.42% | Short Ratio | 8.93 | Perf Half Y | 19.07% |
| Sales | 0.32B | P/B | 0.69 | EPS next 5Y | - | ROA | -9.67% | Short Interest | 1.82M | Perf YTD | 12.83% |
| Book/sh | 17.56 | P/C | 0.79 | EPS past 3/5Y | - | ROE | -12.42% | 52W High | -17.86% ($14.67) | Perf Year | -12.74% |
| Cash/sh | 15.19 | P/FCF | 33.6 | Sales past 3/5Y | -37.74% -16.22% | ROIC | -11.7% | 52W Low | 30.69% ($9.22) | Perf 3Y | -85.16% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -801.27% | Gross Margin | 69.24% | Volatility(W/M) | 4.3% 3.46% | Perf 5Y | -94.83% |
| Dividend TTM | - | EV/Sales | -0.02 | Sales Y/Y TTM | -34.03% | Oper. Margin | -5.46% | ATR (14) | 0.47 | Perf 10Y | -66.9% |
| Dividend Ex-Date | 2023/9/18 | Quick Ratio | 4.35 | EPS Q/Q | -224.17% | Profit Margin | -8.08% | RSI (14) | 53.15 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.86 | Sales Q/Q | -27.64% | SMA20 | 0.44% ($12) | Beta | 0.69 | Target Price | $12 |
| Payout | - | Debt/Eq | 0.14 | Earnings | 2026/8/3 | SMA50 | 7.02% ($11.26) | Rel Volume | 0.25 | Prev Close | $12.14 |
| Employees | 380 | LT Debt/Eq | 0.11 | EPS/Sales Surpr. | 56.92% 5.07% | SMA200 | 7.61% ($11.2) | Avg Volume(3M) | 0.20M | Price | $12.05 |
| IPO | 1993/12/30 | Option/Short | Yes/Yes | Trades | 1702 | Volume | 50,945 | Change | -0.74% |
Company
MED is a Consumer Cyclical sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🥗 Medifast (MED) is a U.S. weight management and health nutrition company. Through its flagship brand OPTAVIA, it offers programs that combine meal replacement products with coaching programs via a direct sales model. By linking its coach network with telehealth services, it has built a structure that manages both nutritional intake and lifestyle changes together.
Over the past 1 year, roughly in the middle
18% below its 1-year high.
MED has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -91.7% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Would have changed by -85.2% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 74.2%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
SVAL 0.00%
FSCC 0.00%
LQPE 0.00%
JPSE 0.00%
FNDA 0.00%Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
IHI 3.2B
SBIO 239M
LFSC 126M
BUZZ 99M
SOCL 90MIt ranks #4 in the industry
Based on market cap of $135M.
MED $135M PER -
ROL $17B PER 31.4
SCI $11B PER 20.8
ANDG $6B PER 6.2
FAQ
What kind of company is MED?
MED belongs to the Consumer Cyclical sector and operates in the Personal Services industry.
What is the market cap of MED?
The market cap of MED is approximately $135M, ranking 4,383 within its sector.
What is the 52-week high and low for MED?
MED has recorded a 52-week high of $14.67 and a low of $9.22.
